Quintiles Transnational announces clinical pharmacology alliance with AstraZeneca - Zibb.com

Nov 03, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --

Quintiles Transnational Corp. has entered into a clinical pharmacology agreement with AstraZeneca plc, a UK-based pharmaceutical company, to deliver AstraZeneca's clinical pharmacology studies across multiple therapy areas and around the globe. Quintiles is a US-based biopharmaceutical services company.

Deal Type    Partnership
Sub-Category Other
Deal Status  Announced: 2009-11-02

Partner 1 (Company) Quintiles Transnational Corp.
Partner 2 (Company) AstraZeneca PLC

Read more...

Tags: clinical   partnership   pharmaceuticals  

Companies: AstraZeneca PLC (AZN)

Permalink

AstraZeneca PLC (ADR) (AZN) Corporate Event Announcement Notice - Zibb.com

Oct 29, 2009 (Wall Street Horizon via COMTEX) --

AstraZeneca PLC (ADR) (AZN)

Expected next earnings release:
Announcement date: 10/29/2009 - Before Market
Earnings Quarter: Q3
Announcement Status: Verified

Expected next investor conference call information:
Conference Call Date: 10/29/2009
Conference Call Time (ET): 9:00 AM
Conference Call URL:

Read more...

Tags: conference   corporate   earnings   market  

Companies: AstraZeneca PLC (AZN)

Permalink

Research and Markets: AstraZeneca plc 2009 Fortune Global 500 Snapshot Company Profile for those in

Dublin, Nov 03, 2009 (M2 PRESSWIRE via COMTEX) --

Research and Markets(http://www.researchandmarkets.com/research/413ff5/astrazeneca_plc_20) has announced the addition of the "AstraZeneca plc 2009 Fortune Global 500 Snapshot Company Profile" company profile to their offering.

This report provides in-depth company profiles for AstraZeneca plc as ranked in the 2009 Fortune Global 500 list. All data is gathered from primary source. Reports are available in easily accessible PDF format and data is consistently presented. Data is regularly tracked and enhanced to ensure data on these high profile companies is accurate and current. This report is an indispensable tool for investors wanting to gather the relevant facts on the major companies in Asia Pacific. The author concentrates on a small number of high profile companies using tested and trusted research and editorial methodologies.

Read more...

Tags: asia   dividends   email   e-mail   eps   equity   executive   investment opinion   medical   research   sales   trade   united kingdom   web  

Companies: AstraZeneca PLC (AZN)

Permalink

AstraZeneca (AZN) Approaching New 52-Week High - Zibb.com

Oct 30, 2009 (Fresh Brewed Media via COMTEX) --

AstraZeneca (NYSE: AZN) closed yesterday at $45.75. So far the stock has hit a 52-week low of $29.96 and 52-week high of $47.61. AstraZeneca stock has been showing support around 44.81 and resistance in the 46.25 range. Technical indicators for the stock are Bullish and S&P gives AZN a neutral 3 STAR (out of 5) hold rating. AZN appears on the Investors Observer Hedged Dividend Income list. For a hedged play on this stock, look at a Dec '09 45 covered call (AZN LI) for a net debit in the $43.70 area. That is also the break even stock price for this trade. This covered call has a 50 day duration, provides 4.48% downside protection and a 2.97% assigned return rate for a 21.72% annualized return rate (comparison purposes only). A lower cost hedged play for this stock would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the AZN Jan '11 30 Call (OXU AF) and selling the Dec '09 45 call (AZN LI) for a $13.90 debit. The trade has a 50 day life and would provide 4.04% downside protection and a 7.91% assigned return rate for a 58.00% annualized return rate (for comparison purposes only). AstraZeneca has a current annual dividend yield of 4.52%.

FBB-Seven Summits Research Goto www.iotogo.com/18w1 for our free report titled, The 18 Ways To Know When It's Time To Dump A Stock

Tags: dividend   investment opinion   nyse   research   S&P   trade   yield  

Companies: AstraZeneca PLC (AZN)

Permalink